Exforge antitrust settlement caps Novartis’ year of legal disputes
Pharmaceutical Technology
JANUARY 6, 2023
In a press release, the company said a generic launch would damage sales in FY 2023 by $300,000. Ex-Novartis sales representative Steven Camburn filed a whistleblower case that claimed Novartis had paid doctors up to $3,500 to participate in educational speaker programs to increase the promotion and prescription of Gilenya.
97 
Let's personalize your content